[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646382":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":24,"collaborators":28,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":39,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":10,"studyType":45,"phases":10,"briefSummary":46,"conditions":47,"keywords":10,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":10},{"fullName":5,"class":6},"National and Kapodistrian University of Athens","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Epithelial Ovarian Cancer",null,"Women with epithelial ovarian cancer prior to surgical intervention or treatment. Participants present with an adnexal mass suspicious of ovarian cancer and are subsequently classified based on histopathological diagnosis.",[13],"Diagnostic Test: Investigational ovarian cancer biomarker assays",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy controls","Healthy controls without a cancer diagnosis recruited for comparison with participants with epithelial ovarian cancer.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Investigational ovarian cancer biomarker assays","Collection of blood samples for investigational ovarian cancer biomarker analyses (OVA-GLY, OVA-VOC and OVA-miRNA).",[9,15],{"type":25,"investigatorFullName":26,"investigatorTitle":27,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Michael Liontos","Assistant Professor of Medical Oncology",[29],{"name":30,"class":6},"European Commission","100646382","disarm-clinical-study-b-evaluation-of-innovative-ovarian-cancer-biomarker-assays-100646382",false,"NCT07693894","DISARM Clinical Study B: Evaluation of Innovative Ovarian Cancer Biomarker Assays","Multi-site, Multi-country Evaluation of Innovative Ovarian Cancer Biomarker Assays. (DISARM Clinical Study B-CSB)","DISARM CSB","Inclusion Criteria:\n\nEOC patients\n\n1. Women, trans men and non-binary people with female reproductive organs\n2. Aged ≥35 years\\*\n3. Pathologically diagnosed, by biopsy, with EOC prior to surgical intervention or treatment\n4. Presenting with adnexal mass suspicious of OC on imaging and scheduled for surgical resection or biopsy (and subsequent confirmation of EOC)\n5. Able to give informed consent\n\nHealthy controls\n\n1. Women, trans men and non-binary people with female reproductive organs\n2. Aged ≥35 years\n3. No cancer history\n4. Able to give informed consent\n\nExclusion Criteria:\n\n1. Prior history and any treatment for malignancy\n2. Prior removal of either ovary for any reason\n3. Pregnant or lactating\n4. Any condition or circumstance that, in the opinion of the investigator, could interfere with the participant's ability to participate or comply with study requirements",true,"FEMALE","35 Years",{"count":43,"type":44},2080,"ESTIMATED","OBSERVATIONAL","Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes.\n\nRecent research has focused on the development of blood-based tests, sometimes referred to as liquid biopsy tests, which aim to look for changes in the blood that could be linked to cancer. These tests are still under investigation and are not part of routine clinical care.\n\nThe purpose of this study is to evaluate several blood-based ovarian cancer tests. This will be done by comparing test results from people who have ovarian cancer with results from people who do not have cancer.\n\nThe study will also collect information from standard blood tests and genetic analyses to better understand how these results relate to ovarian cancer.\n\nThis study is for research purposes only. The blood-based tests being evaluated are investigational and are not used to make medical decisions or diagnoses for women taking part in the study.",[48],"Ovarian Cancer","NOT_YET_RECRUITING","2026-07-05",{"date":52,"type":53},"2026-07-09","ACTUAL",{"date":55,"type":44},"2026-07",{"date":57,"type":44},"2028-12",{"name":5,"class":6}]